In patients with psoriasis, those who take apremilast have similar rates of anxiety and depression as patients prescribed other non-corticosteroid systemic psoriasis treatments, according to study results published in the Journal of the European Academy of Dermatology and Venereology.

Little is known about whether systemic treatments for psoriasis and psoriatic arthritis (PsA) are associated with an increased risk for anxiety and depression and whether these risks differ in both treatments. Therefore, the researchers sought to quantify the risk for incident-treated anxiety, depression, and mixed anxiety plus depression in patients treated with apremilast compared with patients prescribed other treatments for psoriasis and PsA.

They found that among the 31,274 patients with psoriasis (43.1% women, median age 49.3 years), patients treated with apremilast alone (n=3913, 12.5%) had a similar risk for incident-treated depression, anxiety, and anxiety plus depression compared with patients treated with conventional disease modifying antirheumatic drugs (n=56511, 20.8%) or biologic monotherapies. In 30,426 patients with PsA (43.6% women, median age 52.9 years), similar rates were noted for incident-treated depression and anxiety plus depression regardless of treatment; however, apremilast alone was associated with a slightly increased risk for treated anxiety compared with other PsA treatments even after adjustment for demographics and history of psychiatric disorders.

The investigators concluded that, Overall, the results of this study provide reassurance that apremilast used for the treatment of psoriasis or PsA is not associated with a high risk for incident treated depression, anxiety, anxiety [plus] depression. They added that, Among PsA patients, users of apremilast had similar rates of depression and anxiety [plus} depression compared to users of other systemic noncorticosteroid PsA drugs; however, the rate of anxiety was slightly higher.

Disclosure: This clinical trial was supported by Celgene Corporation (Summit, NJ 07901). Please see the original reference for a full list of authors disclosures.

Follow @DermAdvisor

Reference

Vasilakis-Scaramozza C, Persson R, Hagberg KW, Jick S. The risk of treated anxiety and treated depression among patients with psoriasis and PsA treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database [published online January 25, 2020]. J Eur Acad Dermatol Venereol. doi: 10.1111/jdv.16231

Follow this link:

Rates of Anxiety, Depression with Apremilast vs Other Psoriasis Treatments - Dermatology Advisor

Alopecia left Tayshan too anxious to leave the house (Picture: Earth Elixir)

A woman who suffered for years with psoriasis on her scalp and significant hair loss has created her own all-natural haircare brand because the prescribed treatments for these conditions didnt work for Afro hair.

Tayshan, from Streatham, south London, had painful psoriasis on her scalp that caused hair loss and, eventually, alopecia. She also struggled with hair growth, with her hair never reaching past her shoulders.

I would go to the doctors and they would recommend another shampoo telling me to wash my hair three times a day, or suggest another steroid cream, Tayshan tells Metro.co.uk. They had no understanding of Afro hair at all and the damage that would be caused with these products.

Hair was always really important for Tayshan, and she says her experience with psoriasis and alopecia gave her such bad anxiety that she didnt even want to leave the house.

I felt so embarrassed that people could either see flakes from the psoriasis or bald patches from the alopecia, she says.

As women of colour we grow up with such emphasis put on our hair and are told that it is intricately tied to our beauty. I really suffered with that growing up, being mixed-race and not having the typical loose curls that people associate with being mixed-race I had grown up really fixating on my hair.

So, suddenly having bald patches everywhere I really felt like I had lost part of my identity.

At the time, Tayshan was also pregnant with her second child and was conscious that the products that she was putting on her scalp could be absorbed into her body and she didnt want that for her baby.

I decided enough was enough and started exploring the natural path of hair care, says Tayshan. Through a lot of research, trials, tribulations and testing I decided I was going to make my own natural products, as everything on the market includes ingredients that arent actually good for our hair or skin.

Tayshan, who has a degree in forensic science, also took inspiration from her daughter when creating her products.

I really wanted her to enjoy her curls, coils and kinks and embrace her hair, explains Tayshan. I didnt want her to spend her whole childhood not enjoying her hair and wishing it was like other peoples. I also wanted to have products that I knew I could use on her that was completely natural.

Tayshan has now been making her own products for two years, and she says the change in the quality, health and length of her hair has been unbelievable.

Not only is the growth astounding but it has never felt so healthy, shiny, strong, thick and my bald patches have completely gone! she says.

After sharing some products with family and friends I was encouraged to sell my products so everyone can try them. So I launched my brand Earth Elixir a range of homemade hair care products made using natural ingredients from the earth, primarily Ayurvedic herbs, which I created three weeks after my third child was born.

Tayshans products are natural, organic and entirely vegan, they include an Ayurvedic hair oil, a shea, mango and chebe whip, and a leave-in hair tea set

I also want woman to know that they can follow their dreams and nothing should stop them, says Tayshan. Many said that I wouldnt be able to do it with a seven-year-old, a 14-month-old and a newborn baby, but I have done it, customers are loving it and feedback has been amazing.

Tayshan hopes her products can give other black and mixed-race women healthier curls, kinks and coils and help to improve their confidence.

Have you created your own business or achieved something against the odds?

Get in touch: metrolifestyleteam@metro.co.uk.

MORE: How to deal with coronavirus panic when youre experiencing health anxiety

MORE: Racism and damaging stereotypes prevent east Asian women from taking part in sport

MORE: BAME millennials much more likely to be in unstable jobs than white workers

Read more here:

Woman creates Afro hair care brand to help with her scalp psoriasis - Metro.co.uk

Fourth Quarter Highlighted by Presentation of Positive DUR-928 Phase 2a Alcoholic Hepatitis Data at the Liver Meeting 2019

Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time

CUPERTINO, Calif., March 3, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2019 and provided a corporate update.

"The highlight of the year for DURECT in 2019 was achieving positive results from our DUR-928 Phase 2a alcoholic hepatitis (AH) study, which were featured in multiple presentations at the Liver Meeting 2019, including a late-breaking oral presentation by Dr. Tarek Hassanein," stated James E. Brown, D.V.M., President and CEO of DURECT. "In addition, we have already exceeded our 60 patient enrollment target in the ongoing NASH trial, and the last patient is scheduled to begin the 28-day dosing period next week. We are on track to announce top-line NASH data mid-year. We are also making steady progress toward starting a Phase 2b AH clinical trial by mid-year. In January 2020, the FDA held an Advisory Committee meeting to discuss our POSIMIR NDA resubmission. Subsequently, we have continued to interact with FDA as they continue their review."

Potential major milestones in 2020:

Update on Selected Programs and Transactions:

Epigenetic Regulator Program. DUR-928, the lead product candidate in the Company's Epigenetic Regulator Program, is an endogenous, orally bioavailable, first-in-class small molecule, which may have broad applicability in acute organ injuries such as AH, and in chronic liver diseases such as non-alcoholic steatohepatitis (NASH).

Clinical Trials

Alcoholic Hepatitis (AH)

Non-Alcoholic Steatohepatitis (NASH)

Psoriasis

POSIMIR (bupivacaine extended-release solution) Post-Operative Pain Relief Depot. POSIMIR is the Company's investigational post-operative pain relief depot that uses the Company's patented SABER technology and is designed to deliver bupivacaine to provide up to 3 days of pain relief after surgery.

Gilead Collaboration. Theinvestigational long-acting injectable HIV product using DURECT's SABER technology under development with Gilead is currently being re-formulated and will undergo additional pre-clinical development work.

Debt Amendment. In December 2019, the Company amended its existing $20 million term loan with Oxford Finance such that principal payments will commence 18 months later than previously scheduled (i.e., commencing December 1, 2021 rather than June 1, 2020) and the final maturity date has been moved back by 18 months (i.e., from November 1, 2022 to May 1, 2024). The interest rate and final payment remain unchanged, and the Company paid Oxford Finance an amendment fee of $825,000.

Earnings Conference Call

We will host a conference call today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss fourth quarter 2019 results and provide a corporate update:

A live audio webcast of the presentation will be also available by accessing DURECT's homepage at http://www.durect.com and clicking "Investors." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under "Event Calendar" in the "Investors" section.

About DURECT Corporation

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DURECT's lead candidate, DUR-928, has demonstrated the ability to regulate the expression of genes involved in lipid metabolism, inflammatory responses and cell survival. This drug candidate is currently in Phase 2 development for the treatment of alcoholic hepatitis (AH) and Phase 1 development for the treatment of nonalcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. A key product candidate in this category is POSIMIR (bupivacaine extended-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. DURECT has also entered into an agreement with Gilead Sciences to develop and commercialize a long-acting injectable HIV investigational product using DURECT's SABERtechnology. For more information about DURECT, please visit http://www.durect.com.

Story continues

DURECT Forward-Looking Statement

The statements in this press release regarding clinical development and plans for DUR-928, including plans to announce top-line data from the Phase 1b NASH trial by mid-year, and initiate a Phase 2b trial of DUR-928 in AH by mid-year, potential regulatory approval of POSIMIR, potential commercial relationships for POSIMIR if approved or other license and collaboration agreements, and the potential benefits and uses of our drug candidates, including the potential use of DUR-928 to treat acute organ injuries such as AH and chronic liver diseases such as NASH , are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that future clinical trials of DUR-928 are not started when anticipated, take longer to conduct than anticipated, do not replicate the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy of DUR-928 in a statistically significant manner, the risk that the FDA will not approve POSIMIR, the risk that additional time and resources may be required for development, testing and regulatory approval of DUR-928 or POSIMIR, potential adverse effects arising from the testing or use of our drug candidates, our potential failure to successfully re-formulate the investigational long-acting injectable HIV product under development with Gilead, our potential failure to maintain our collaborative agreements with third parties or consummate new collaborations and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on November 5, 2019 under the heading "Risk Factors."

NOTE: POSIMIR and SABER are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. DUR-928 and POSIMIR are investigational drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.

DURECT CORPORATION

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except per share amounts)

(unaudited)

Three months ended

Twelve months ended

December 31

December 31

2019

2018

2019

2018

Collaborative research and development and other revenue

$ 7,249

$ 775

$ 18,129

$ 8,207

Product revenue, net

3,436

2,852

11,435

10,357

Total revenues

10,685

3,627

29,564

18,564

Operating expenses:

Cost of product revenues

1,397

1,093

4,143

4,263

Research and development

9,454

5,887

30,209

25,501

Selling, general and administrative

3,794

3,539

14,363

12,419

Total operating expenses

14,645

10,519

48,715

42,183

Loss from operations

(3,960)

(6,892)

(19,151)

(23,619)

Other income (expense):

Interest and other income

338

238

1,074

870

Interest and other expense

(609)

(645)

(2,501)

(2,573)

Net other expense

(271)

(407)

(1,427)

(1,703)

Net loss

$ (4,231)

$ (7,299)

$(20,578)

$(25,322)

Net loss per share

Read the rest here:

DURECT Corporation Announces Fourth Quarter and Full Year 2019 Financial Results and Update of Programs - Yahoo Finance

We have all experienced stress in some form or another, whetherfor a shortor long period of time. This emotional tension stems from unavoidable parts of everyday life, including work, family problems, financial woes and the digital pressures of social media.

While the anxiety that arises may originally occur in your brain, the consequences can play out physically. And no, we dont just mean tense shoulders and furrowed brows.

According to dermatologist Dr Anil Budh-Raja, daily stressors can also manifest in your skin, triggering or worsening a wide range of conditions such as acne, psoriasis, eczema and even hair thinning. Stress causes a change in brain and body chemistry and has a significant impact on our skin, Dr Budh-Raja explains, describing the process as the brain-skin connection.

Sharing the full story, not just the headlines

To understand how stress and anxiety can affect the skin, Dr Budh-Raja says we must first understand a little about the endocrine system.

The endocrine system is comprised of a number of glands that produce hormones and, when everything is in place, it allows the human body to work like a well-oiled machine. However, when outside factorssuch as stressintervene, this intricate system can slip out of sync.

During moments of tension the body produces excess cortisol, often referred to as the stress hormone, which wreaks havoc on everything from your immune system to blood pressure. Stress increases cortisol production from the adrenal glands, which in turn increases sebaceous gland activity, to produce more oil and sebum, Dr Budh-Raja explains.

The result can be acne and increased sensitivity of our skin. Cortisol also weakens the skins immune system, leading to oxidative stress which manifests itself as wrinkles, lines and lacklustre skin.

It also increases inflammation on the body and conditions like eczema, rosacea and psoriasis can flare up.

Dr Sarah Coles, a chartered clinical psychologist, agrees, adding that the onset and consequences of stress can often form a vicious cycle.

Anxiety and/or stress, which can be caused by skin conditions such as eczema, in fact can exacerbate the condition due to the bodys inflammatory responses such as producing cortisol or interrupting sleep, Coles says.

On Thursday, a series of photos titled How Do You C Me Now? were exhibited at the Oxo Tower Wharf in London to inspire the world to love the skin you are in

Brock Elbank/SWNS

The models featured in the photos, taken by London-based photographer Brock Elbank, live with a potentially life-threatening skin condition called congenital melanocytic naevus (CMN)

Brock Elbank/SWNS

According to the National Organisation of Rare Disorders (NORD), CMN are visible pigmented proliferations in the skin that are present at birth that can cover up to 80 per cent of the body. CMN are a known risk factor for melanoma - a type of cancer that develops from the pigment-containing cells

Brock Elbank/SWNS

CMN can be light brown to black patches or plaques, can present in variable ways, and cover nearly any size surface area or any part of the body, NORD states

Brock Elbank/SWNS

Small to medium CMN are predicted to occur in more than one in a 100 births while large and especially giant CMN (covering a a predicted diameter at adult age of at least 20 cm on the body) are estimated to present themselves in around 1 in 50,000 births

Brock Elbank/SWNS

The exhibition, which is being supported by UK CMN charity Caring Matters Now, has been presented throughout 30 different portraits and aims to challenge "conventional perceptions of beauty"

Brock Elbank/SWNS

A spokesperson from Caring Matters Now says: People with CMN often feel isolated due to the rarity of the condition and have to deal with negative comments because of their visible difference, resulting in low self-esteem"

Brock Elbank/SWNS

Several of the individuals photographed for the exhibition have never shown their birthmarks in public before.

Brock Elbank/SWNS

In a world where people work hard to stand out from the crowd, 'How Do You C Me Now?' aims to celebrate diversity and educate the public about this rare condition," a spokesperson from the charity added

Brock Elbank/SWNS

Admission to the exhibition is free and will run for 10 days before touring the world

Brock Elbank/SWNS

On Thursday, a series of photos titled How Do You C Me Now? were exhibited at the Oxo Tower Wharf in London to inspire the world to love the skin you are in

Brock Elbank/SWNS

The models featured in the photos, taken by London-based photographer Brock Elbank, live with a potentially life-threatening skin condition called congenital melanocytic naevus (CMN)

Brock Elbank/SWNS

According to the National Organisation of Rare Disorders (NORD), CMN are visible pigmented proliferations in the skin that are present at birth that can cover up to 80 per cent of the body. CMN are a known risk factor for melanoma - a type of cancer that develops from the pigment-containing cells

Brock Elbank/SWNS

CMN can be light brown to black patches or plaques, can present in variable ways, and cover nearly any size surface area or any part of the body, NORD states

Brock Elbank/SWNS

Small to medium CMN are predicted to occur in more than one in a 100 births while large and especially giant CMN (covering a a predicted diameter at adult age of at least 20 cm on the body) are estimated to present themselves in around 1 in 50,000 births

Brock Elbank/SWNS

The exhibition, which is being supported by UK CMN charity Caring Matters Now, has been presented throughout 30 different portraits and aims to challenge "conventional perceptions of beauty"

Brock Elbank/SWNS

A spokesperson from Caring Matters Now says: People with CMN often feel isolated due to the rarity of the condition and have to deal with negative comments because of their visible difference, resulting in low self-esteem"

Brock Elbank/SWNS

Several of the individuals photographed for the exhibition have never shown their birthmarks in public before.

Brock Elbank/SWNS

In a world where people work hard to stand out from the crowd, 'How Do You C Me Now?' aims to celebrate diversity and educate the public about this rare condition," a spokesperson from the charity added

Brock Elbank/SWNS

Admission to the exhibition is free and will run for 10 days before touring the world

Brock Elbank/SWNS

Stress can also make us less likely to engage in healthy habits, for example,we might work longer hours, eat less well, or drink more caffeine and alcohol.

When troubles are piling up, it can often feel like the worst time for pimples to populate your face, but they often do. While it can be frustrating, science says it makes perfect sense for stress to exhibit itself physically.

A 2015 study into the effects of stress as a causative or maintaining factor in psoriasis showed that about half of participants said their first experience with the disease came during a particularly difficult time in their lives, while 63 per cent said their symptoms worsened when they felt anxious or under pressure.

Similarly, a separate 2017 study of female medical students found that for 74 per cent of participants, anxiety and stress were exacerbating factors of their acne.

Thankfully, experts suggest that much of the skin damage caused by stress can be mitigated by focusing on daily moments of self-care.

When it comes to looking after your skin during periods of extreme stress, Dr Adam Friedmann, a consultant dermatologist, recommends eating a healthy balanced diet, protecting the skin from UV rays using a high factor SPF and incorporating a moisturiser that contains anti-inflammatory ingredients into your skincare routine to help improve any redness, flaking or itching.

Dr Budh-Raja agrees, advising that anyone with stressed out skin invests in products that contain soothing ingredients such as aloe vera, chamomile, oatmeal, rosemary extract and niacinamide, which restores the surface of skin against moisture loss and dehydration.

While it is good to know that we can find remedies to help counteract the effects of anxiety on the beauty counter, Dr Coles says it is also important to address the root of the problem and to try tomanage stress levels using alleviation techniques such as yoga and meditation.

There are lots of ways to manage stress in daily life, for example having a good sleep routine consisting of settling in a dark room with no bright screens an hour before bed and waking up at the same time each day, Coles says.

It is also important to have a good repertoire of coping strategies for managing stress that work for you. I like to think of this as having a menu to choose from as different strategies often help in different situations.

She continues: For some people this might be going for a long walk, spending some time outside, reading, talking with a friend, mediation, yoga, or some other form of exercise.

So if you know youre about to enter a stressful period, try to build in time for the activities that will help you to feel calm and rested your skin will thank you.

Originally posted here:

How stress affects your skin and what to do about it, according to experts - The Independent

Favorable safety profile is a substantial benefit in the treatment of chronic diseases that require long-term dosing

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biopharmaceutical company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it is submitting its annual Drug Safety Update Reports (DSUR) for both Piclidenoson and Namodenoson to the governing health regulatory agencies where its drug candidates are currently treating patients. Submission of the DSUR is an annual requirement for investigational-stage new drugs under development in territories which subscribe to the International Council for Harmonization guidelines, including the U.S. Food and Drug Administration and the European Medicines Agency. The DSUR includes updates on drug safety information such as adverse events, suspected unexpected serious adverse reactions, and other indicators of potential risk. Can-Fites reports being filed this year extend the growing body of documentation showing both Piclidenoson and Namodenoson have favorable safety profiles and risk-benefit ratios in more than 1,500 patients.

Dr. Michael Silverman, M.D., Can-Fites Medical Director, commented, "We welcome the opportunity to compile our cumulative data on a regular basis, as afforded by the DSUR process. As in years past, these snapshots of our safety data continue to confirm that both of our A3AR drugs in development are well-tolerated. We are pleased that there are no emerging safety concerns that could put patients at risk or impede our efforts to develop new drugs to meet unmet patient needs. These latest data are particularly robust, as we have achieved over 50% enrollment in both of our Phase III studies for Piclidenoson, as well as having completed two Phase II trials for Namodenoson."

Piclidenoson is currently in two Phase III studies, one for the treatment of moderate-to-severe psoriasis to establish superiority versus placebo and non-inferiority versus Otezla with over 50% of the planned 407 patients already enrolled; and another for the treatment of moderate-to-severe rheumatoid arthritis in newly diagnosed patients to establish non-inferiority to MTX, the standard of care, with over 50% of the planned 500 patients enrolled, and an interim analysis is planned. Namodenoson has completed a 78-patient Phase II study in liver cancer, and Can-Fite is currently preparing for a Phase III trial in this indication. Namodenoson has also recently completed enrollment in a 60 patient Phase II study in the treatment of NASH, with topline results expected later this month.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: http://www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fites expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fites authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fites actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fites actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fites filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005502/en/

Contacts

Can-Fite BioPharmaMotti Farbsteininfo@canfite.com +972-3-9241114

Originally posted here:

Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results from Phase II and Phase III Studies of Namodenoson and Piclidenoson -...

As common as psoriasis may be, the autoimmune condition, which typically presents as rash-like scales on the skin, poses a unique challenge for those who wear makeup. Many people with the flaky, often red patches psoriasis causes want to conceal the condition's most visible symptom, but those plaques are also especially difficult to conceal. Where daily makeup application may be an afterthought for those who don't have psoriasis, those who do may not know how to apply foundation and concealer without emphasizing the roughness of their patches or further upsetting their skin.

"Applying makeup to psoriasis is challenging because plaque psoriasis has scales that can be uncomfortable and easily irritated," says makeup artist Dana Rae Ashburn. "You don't want to make the area look worse by piling on product. And you also don't want to make the affected area appear even more dry."

We spoke to Ashburn and other experts to determine the safest and most effective approach to applying makeup when you have psoriasis so you can feel confident, even during flare-ups.

How should psoriatic skin be prepped for makeup?

Complexion makeup can get caked up if applied over dry, scaly, thick psoriatic skin, according to New Jersey dermatologist Shari Sperling, which is why she emphasizes the importance of preparing skin for makeup. "You should moisturize and use products that help to soften the skin prior to applying makeup," she tells Allure.

Makeup artist Meredith Baraf couldn't agree more, urging head-to-toe moisturizer application. "Make sure to give extra love to any areas ofpsoriasis. You are moisturizing to soothe, soften, and hydrate your skin," she tells Allure. "By doing this you are also prepping your skin for seamless coverage of any areas ofpsoriasis."

Ashburn's favorite pre-makeup moisturizer for psoriatic skin is the Allure Best of Beauty and Readers' Choice Award winner CeraVe Moisturizing Cream, which can be used on both body and face. She also recommends following that with a hydrating primer such as 100% Pure's Luminous Primer.

What kind of makeup ingredients should you avoid?

As important as moisturizing ingredients are to the look and feel of skin with psoriasis, it's also important to avoid other types of ingredients and some are quite common.

"People with psoriasis should avoid ingredients like fragrances and dyes, as they are known to irritate your skin," Sperling tells Allure. "Also, alcohol in products can dry your skin out."

How should I apply foundation to psoriatic skin?

As tempting as it may feel to pile on heavy, full-coverage foundation, both Ashburn who often refrains from covering her own psoriasis with makeup and Baraf say it's best to keep it simple. "In my opinion, the fewer the products and steps, the better," she says. "You don't want to irritate or aggravate the area in the process of covering."

The two makeup artists also agree that when it comes to foundation buildable is best. "Look for a foundation that has sheer to buildable coverage not mattifying, but has a good amount of pigment," Ashburn suggests. Her favorite is lightweight Ilia True Skin Serum Foundation. Baraf likes Dior Diorskin Forever Undercover Foundation.

No matter what foundation you choose, the way you apply it really matters. "Remember that the tools you use to apply your foundation play a huge role in the payoff of the product you are applying," Baraf tells Allure, explaining that her approach to coveringpsoriasison the face is to apply foundation as she would to non-psoriatic skin.

See more here:

How to Apply Makeup to Skin With Psoriasis Expert Tips - Allure

Alwan, W., and F.O. Nestle. "Pathogenesis and Treatment of Psoriasis: Exploiting Pathophysiological Pathways for Precision Medicine." Clin Exp Rheumatol 33 (Suppl. 93): S2-S6.

Arndt, Kenneth A., eds., et al. "Topical Therapies for Psoriasis." Seminars in Cutaneous Medicine and Surgery 35.2S Mar. 2016: S35-S46.

Benhadou, Fairda, Dillon Mintoff, and Vronique del Marmol. "Psoriasis: Keratinocytes or Immune Cells -- Which Is the Trigger?" Dermatology Dec. 19, 2018.

Conrad, Curdin, Michel Gilliet. "Psoriasis: From Pathogenesis to Targeted Therapies." Clinical Reviews in Allergy & Immunology Jan. 18, 2015.

Dowlatshahi, E.A., E.A.M van der Voort, L.R. Arends, and T. Nijsten. "Markers of Systemic Inflammation in Psoriasis: A Systematic Review and Meta-Analysis." British Journal of Dermatology 169.2 Aug. 2013: 266-282.

Georgescu, Simona-Roxana, et al. "Advances in Understanding the Immunological Pathways in Psoriasis." International Journal of Molecular Sciences 20.739 Feb. 10, 2019: 2-17.

Greb, Jacqueline E., et al. "Psoriasis." Nature Reviews Disease Primers 2 (2016): 1-17.

Kaushik, Shivani B., and Mark G. Lebwohl. "Review of Safety and Efficacy of Approved Systemic Psoriasis Therapies." International Journal of Dermatology 2018.

National Psoriasis Foundation. "Systemic Treatments: Biologics and Oral Treatments." 1-25.

Ogawa, Eisaku, Yuki Sato, Akane Minagawa, and Ryuhei Okuyama. "Pathogenesis of Psoriasis and Development of Treatment." The Journal of Dermatology 2017: 1-9.

Stiff, Katherine M., Katelyn R. Glines, Caroline L. Porter, Abigail Cline & StevenR. Feldman. "Current pharmacological treatment guidelines for psoriasis and psoriaticarthritis." Expert Review of Clinical Pharmacology (2018).

Villaseor-Park, Jennifer, David Wheeler, and Lisa Grandinetti. "Psoriasis: Evolving Treatment for a Complex Disease." Cleveland Clinic Journal of Medicine 79.6 June 2012: 413-423.

Woo, Yu Ri, Dae Ho Cho, and Hyun Jeong Park. "Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis." International Journal of Molecular Sciences 18 Dec. 11, 2017: 1-26.

View original post here:

Psoriasis: Types, Pictures, Causes, Symptoms, Treatments & Diet

The combination of apremilast with biologics is safe and associated with reductions in the mean Psoriasis Area and Severity Index (PASI) score in patients with psoriasis who have recently shown biologic fatigue, according to study results published in the Journal of Dermatology.

The study was a retrospective analysis of efficacy and safety results of a combination psoriasis treatment regimen consisting of apremilast and biologics (n=14). Patients included in the analysis were initially treated with 1 biologic, but after the efficacy of the biologic(s) declined, apremilast was added to the existing treatment program. Biologics included infliximab, adalimumab, secukinumab, ixekizumab, and ustekinumab.

Changes in the PASI score, as well as achievement of 75% and 50% reductions in PASI Score (PASI-75 and PASI-50, respectively), were assessed at weeks 0, 12, and 24 after the apremilast addition.

A total of 11 patients achieved a 90% improvement in PASI score after biologic therapy, with the lowest PASI scores ranging from 0 to 3.8 (mean, 1.30.3). Prior to biologic treatment, PASI scores in the overall cohort ranged from 5.9 to 39.0 (mean, 19.52.7). The mean PASI score before the addition of apremilast to biologic therapy was 3.20.4. The addition of apremilast to the existing biologic treatment protocol decreased the mean PASI score to 1.60.3 at 24-week follow-up. Approximately 50% of patients had achieved PASI-50, whereas only 29% achieved PASI-75 at 24 weeks.

There were 4 patients who developed diarrhea during the 24 weeks and 1 patient reported both diarrhea and nausea. In 2 patients, weight loss >5% of body weight occurred. Adverse events were not severe enough to cause any patient to discontinue the combination treatment.

Study limitations were the small number of patients, the inclusion of only patients with biologic fatigue, and its retrospective nature.

Based on their findings, the investigators concluded that apremilast could be safely combined with a biologic in psoriatic patients who are not responding adequately to a biologic alone.

Follow @DermAdvisor

Reference

Takamura S, Sugai S, Taguchi R, Teraki Y. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue [published online December 22, 2019]. J Dermatol. doi:10.1111/1346-8138.15193

Read more here:

Addition of Apremilast to Biologic Therapy Is Successful for Treating Psoriasis in Biologic Fatigue - Dermatology Advisor

Image: Joshua Coppola, scientist, engineering, lab automation, works alongside his robotic lab partner, Venus. Source: AbbVie.

By Manas Mishra

(Reuters) - AbbVie Inc on Friday forecast 2020 earnings above Wall Street estimates as the drugmaker expects growth to be powered by its new treatments for psoriasis and rheumatoid arthritis at a time when sales of its blockbuster drug Humira slow.

Shares of Illinois-based AbbVie are up 4.7% to $91.30 in late morning trading.

The drugmaker expects the two treatments, Skyrizi and Rinvoq, to bring in a combined revenue of about $1.70 billion in 2020.

The profit forecast excludes any impact from its $63 billion deal for Botox-maker Allergan Plc, which it expects to close in the first quarter.

The launches of Skyrizi and Rinvoq are going extremely well, Chief Executive Officer Richard Gonzalez said in a statement.

In the fourth quarter, Skyrizi brought in sales of $216 million, topping estimates of $142 million, according to five analysts polled by Refinitiv. Rinvoq, which was approved in August, brought in sales of $33 million.

AbbVie is betting on new treatments and the addition of Botox to its portfolio as it braces for a revenue hit when it loses patent protection for Humira, the worlds best-selling medicine, in its biggest market, the United States, in 2023.

While AbbVie is seeking to shine light on its early stage pipeline, we anticipate the performance of the stock will be heavily tied to ongoing Skyrizi and Rinvoq rollouts, said Citi analyst Andrew Baum.

He expects investors to focus on the delivery of promised savings from the Allergan deal.

Humira has been boosting the companys revenue ever since it was approved to treat psoriasis and rheumatoid arthritis. However, the drugs sales have suffered since new competition entered Europe.

Quarterly sales of the blockbuster drug were largely unchanged compared with a year earlier at $4.92 billion. But it beat expectations of $4.85 billion.

The company forecast 2020 adjusted earnings of between $9.61 and $9.71 per share, ahead of the average analysts estimate of $9.48.

AbbVie reported net profit of $2.80 billion, or $1.88 per share, in the quarter ended Dec. 31, compared with a loss of $1.83 billion, or $1.23 per share, a year earlier when it recorded $4.12 billion in impairment charges.

Excluding items, the drugmaker earned $2.21 per share in the fourth quarter and beat expectations of $2.19.

Net revenue rose 4.8% to $8.70 billion, marginally higher than average analysts estimate of $8.69 billion.

Reporting by Manas Mishra and Tamara Mathias in Bengaluru; Editing by Arun Koyyur.

_____

Source: Reuters

DISCLOSURE:The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer. The author of this article, or a firm that employs the author, is a holder of the following securities mentioned in this article : None

Excerpt from:

AbbVie Forecasts Higher 2020 Profit on New Psoriasis and Arthritis Therapies - Equities.com

(MENAFN - GetNews) Psoriasis Drugs Market Analysis By Key Players, Trends, Insights, Dynamics, Future Outlook, Applications and Segmentation, Forecast to 2025

Psoriasis Drugs Market Size, Growth and Share Analysis By Drug Class [Tumour Necrosis Factor Inhibitors (Adalimumab, Infliximab and Etanercept), Interleukin-Inhibitors (Ustekinumab, Secukinumab, Ixekizumab and Brodalumab), Vitamin D Analogues (Calcitriol, Calcipotriol and Tacalcitol)], Treatment Type {Topicals [Over-the-counter (OTC) Topicals, Topical Non-Steroids and Topical Steroids], Systemic (Retinoid, Cyclosporine and Methotrexate), Biologics [Tumour Necrosis Factor Alpha (TNF-) Inhibitors, InterleU.K.in 12 and 23 (IL-12/23) Inhibitors, Interleukin 17 (IL-17) Inhibitor, T cell Inhibitor]}, Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025

Psoriasis Drugs Market Analysis

The Psoriasis Drugs Market is predicted to touch USD 13.1 billion at a 7.3% CAGR between 2019-2025, states the latest Market Research Future (MRFR) report. Psoriasis, simply put, is an autoimmune condition that causes rapid development of cells on the skin. The overgrowth can result in scaly, thick plaques that may itch and cause discomfort. Scales generally develop on joints, especially the knees and elbows, but it may appear in any part of the body including the face, scalp, neck, feet, and hands.

Various factors are propelling the global Psoriasis Drugs Market growth. Such factors, according to the latest Market Research Future report, include vulnerability towards psoriatic arthritis, favorable reimbursement policies, growing awareness about psoriasis, increasing availability of biosimilars and biologics, aging population and changing lifestyle. Additional factors propelling the growth of the Psoriasis Drugs Market include rising prevalence of autoimmune diseases, increasing incidence of psoriasis, increasing R & D activities for psoriasis treatment, and technological advancements.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2769

On the contrary, lack of knowledge regarding the exact cause of psoriasis and its etiology, the high price of medications with their low efficacy and efficiency, side effects associated with symptomatic treatments, and lack of permanent and effective treatment are factors that may hamper the Psoriasis Drugs Market growth during the forecast period.

Psoriasis Drugs Market Segmentation

The Market Research Future report offers a complete segmental analysis of the Psoriasis Drugs Market based on treatment type and drug class.

By drug class, thePsoriasis treatment Marketis segmented into vitamin D analogues, InterleU.K.in-inhibitors, and tumor necrosis factor inhibitors. The tumor necrosis factor inhibitors segment is again segmented into etanercept, infliximab, and adalimumab. The InterleU.K.in-inhibitors segment is again segmented into brodalumab, ixekizumab, SecU.K.inumab, and ustekinumab. The vitamin D analogues segment is again segmented into tacalcitol, calcipotriol, and calcitriol.

By treatment, the Psoriasis Drugs Market is segmented into biologics, systematic, and topicals. The topicals segment is again segmented into topical steroids, topical non-steroids, and over the counter topicals. The systematic segment is again segmented into methotrexate, cyclosporine, and retinoid. The biologics segment is again segmented into T cell inhibitor, InterleU.K.in 17 (IL-17) inhibitor, InterleU.K.in 12 and 23 (IL-12/23) inhibitors, and tumor necrosis factor-alpha (TNF-a) inhibitors.

Psoriasis Drugs Market Regional Analysis

By region, the Psoriasis Drugs Market report covers the latest trends and growth opportunities across the Americas, Europe, the Asia Pacific, the Middle East and Africa, and Latin America. Of these, North America will spearhead the market during the forecast period. Various factors are propelling the growth of the Psoriasis Drugs Market in the region, such as the growing awareness about psoriasis treatment, rising prevalence of psoriasis, presence of key manufacturers, and increasing health infrastructure.

The Psoriasis Drugs Market in Europe will have the second-largest share during the forecast period. Various factors are propelling the growth of the Psoriasis Drugs Market in the region such as growing awareness about psoriasis, the launch of biosimilars (amzevita, elerzi), and increasing prevalence of psoriasis.

The Psoriasis Drugs Market in the APAC region will grow at the fastest pace during the forecast period. Various factors are propelling the growth of the Psoriasis Drugs Market in the region such as growing geriatric population, large patient pool, improving medical facilities and healthcare infrastructure, increasing participation of key market players, increasing investments to develop new therapeutics to treat psoriasis, and increasing awareness.

The Psoriasis Drugs Market in the MEA will have a small share during the forecast period for the low economic development in Africa.

The Psoriasis Drugs Market in Latin America will have a favorable growth during the forecast period owing to the focus of manufacturers to create novel therapeutics and rise in the psoriasis patient pool.

Psoriasis Drugs Market Key Players

Notable players profiled in the Psoriasis Drugs Market report include Eli Lilly and Company (US), Amgen (US), AbbVie (US), Merck and Co. Inc (US), Pfizer Inc (US), Johnson & Johnson (US), Celgene Corporation (US), AstraZeneca (UK), UCB (Belgium), and Novartis International AG (Switzerland).

Psoriasis Drugs Industry News

Daavlin, a renowned US-based phototherapy units' manufacturer that utilizes therapeutic UV light to effectively and safely treat patients with eczema, vitiligo, and psoriasis have joined hands with HealthLens to give patients better access to receive a dermatology consultation as well as treatment right from their home. The patient just needs to book a consultation online, followed by uploading some pictures of the skin condition and brief health history, after which the information will get electronically encrypted and sent securely to the physician who will respond within 1-2 days.

Browse More Healthcare Related Research Reports at:

Hybrid Operating Room Market Size Analysis, Trends | Application, 2023

CBD Oil Market by Type, Size, Share and Forecast 2024

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Media Contact Company Name: Market Research Future Contact Person: Abhishek Sawant Email: Send Email Phone: +1 646 845 9312 Address: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar City: Pune State: Maharashtra Country: India Website: https://www.marketresearchfuture.com/reports/psoriasis-treatment-market-2769

MENAFN1202202000703268ID1099691955

View post:

Psoriasis Drugs Market Size Is Projected to Reach USD 13.1 Billion at a CAGR of 7.3% By 2025 - MENAFN.COM

Patients with psoriasis who are treated with biologics have a higher risk for hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivations, especially if they are young, hepatitis B surface antigen (HBsAg) seropositive, hepatitis B e-antigen (HBeAg) seropositive, and receiving tumor necrosis factor (TNF)- inhibitor therapy, study data published in the Journal of the American Academy of Dermatology suggest.

University researchers from Taiwan reviewed the medical records of patients with psoriasis who had been treated with TNF- inhibitors, interleukin (IL)-12/23 inhibitors, or IL-17 inhibitors. The investigators used baseline serology to categorize 561 patients with HBV infection into chronic HBV infection, resolved HBV infection, and occult HV infection categories. In addition, a total of 112 patients with HCV infection were included.

Overall, the cohort included 2060 patients with psoriasis treated with biologics between 2009 and 2018. A total of 3562 treatment episodes in the cohort were recorded. At baseline, every 3 months during a treatment episode, and at the end of treatment or follow-up, researchers measured HBV DNA/HCV RNA levels and serum alanine transaminase and aspartate transaminase levels. Reactivations of HBV and HCV viral loads were assessed to examine variables associated with reactivation and biologic-treated psoriasis.

A total of 14 treatment episodes for HCV involved reactivation of the virus during 1522 person-months follow-up (incidence, 110.4/1000 person-years). Univariate and multivariate analyses did not find significant predictors for HCV reactivation. Conversely, reactivation of HBV was observed in 72 treatment episodes for chronic HBV during 3012 person-months follow-up, compared with 3 treatment episodes for occult HBV and 13 for resolved HBV.

Independent risk factors of HBV reactivation in the multivariable model included an absence of antiviral drug prophylaxis, HBsAg positivity, HBeAg positivity, and young age. In HBsAg-positive patients without antiviral prophylaxis, HBeAg positivity was an independent risk factor for HBV reactivation in the adjusted analysis (adjusted hazard ratio [aHR], 3.35; 95% CI, 1.30-8.67; P =.0126). Reactivation of HBV was more common in patients treated with TNF inhibitors vs IL-17 inhibitors (aHR, 2.67; 95% CI, 1.08-6.58; P =.033).

Limitations of the study include its observational design and lack of a comparison group, which the researchers suggest could have consisted of patients with psoriasis but without HCV or HBV infections and who were not treated with biologics.

Although the risk for HCV reactivation seems low in patients with chronic yet stable HCV, the researchers suggest that monitoring of the HCV viral load is still recommended for psoriasis patients with chronic active HCV disease.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Follow @DermAdvisor

Reference

Chiu HY, Chiu YM, Chang Liao NF, et al. Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biological agent: a nine-year multicenter cohort study [published online December 7, 2019]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2019.12.001

View post:

Biologic-Treated Patients With Psoriasis Have Higher Risk for HBV and HCV Reactivations - Dermatology Advisor

Excess body weight places a great strain on nearly all domains of the bodys functions. As the trend of obesity remains unchecked, clinicians will continue to see issues associated with obesity often the result of superficial physiologic reactions to the presence of excess fatty tissue as well as underlying pathophysiologic changes associated with increased adipose fat.1-3

Obesity has many cutaneous manifestations, including striae, intertrigo, plantar hyperkeratosis, lymphedema, acanthosis nigricans, and a greater risk for skin infections and melanoma.1,3 It also contributes to inflammatory dermatologic conditions such as psoriasis and poor wound healing.1

General skin features of people with obesity (defined as a body mass index [BMI] of 30 or higher) are often altered1,3 due to multiple obesity-related factors. A 2017 study3 of American women found that skin barrier and moisturizing functions were significantly impaired by obesity, resulting in considerable dryness and roughness, compared with nonobese women. Skin coloration changes such as facial redness believed to be due to dilation of the local blood vessels in response to inflammation were noted, as was reduced yellow coloration. Conversely, scaliness and roughness were products of systemic inflammation combined with insulin resistance, demonstrated by altered levels of interleukin (IL)-6, leptin, adipokines, and insulin.

Other localized skin manifestations linked to obesity include the following:

The chronic inflammatory skin condition hidradenitis suppurativa is often aggravated by the number and depth of skin folds, which increase with greater weight gain.2,5 This condition generally occurs in the armpit and groin and in skin folds, areas on the body given to friction (skin-to-skin and skin-to-clothing contact) as an individual moves. Hidradenitis suppurativa often begins with follicular plugging, which triggers inflammation and abscess formation.5 Further development into sinus tracts often promotes secondary infection of the area.

Patients with obesity are at higher risk for skin infections such as folliculitis, candidiasis, furunculosis, erythrasma, and tinea cruris as a result of obesity and comorbid conditions such as diabetes and impaired circulation.1,2 These infections most often occur in and around skin folds of the lower genital region and around the breasts, where increased moisture, body heat, and sweating contribute to the colonization of yeast and other bacteria.1,2

Other, more serious conditions may also develop, including the following:

Obesity is associated with a worsened prognosis of psoriasis and is considered an independent risk factor for the development of this chronic inflammatory skin disorder through the production of macrophages from adipose fat.1,6,7 Because visceral adipose fat is increased with obesity, the production of proinflammatory cytokines (including tumor necrosis factor-, IL-6, IL-8, IL-17, IL-18, and monocyte chemoattractant protein-1) and adipokines (such as chemerin, visfatin, leptin, and adiponectin) also increases, stimulating autonomic inflammatory responses.6,7 Reduction of body weight has shown a direct correlation to reduced severity of psoriasis symptoms.1,6,7 Obesity also interferes with the pharmacodynamics of drugs used to treat psoriasis and can increase the risks for adverse events.7

All specialists will continue to see a rise in obesity-related complications, and dermatologists will be called on to treat a wide-ranging conditions related to weight issues. Many of the autonomic characteristics of skin are altered and, in some cases, impaired by obesity. Weight management may soon come under the dermatologists purview as a component of intervention for cutaneous manifestations of obesity, in addition to other treatments.1,2

Follow @EndoAdvisor

References

1. Shipman AR, Millington GWM. Obesity and the skin.Br J Dermatol. 2011;165:743-750.

2. Scheinfeld NS. Obesity and dermatology. Clin Dermatol. 2004;22:303-309.

3. Mori S, Shiraishi A, Epplen K, et al. Characterization of skin function associated with obesity and specific correlation to local/systemic parameters in American women. Lipids Health Dis. 2017;16(1):214.

4. Hahler B. An overview of dermatological conditions commonly associated with the obese patient. Ostomy Wound Manage. 2006;52(6):34-47.

5. Lee EY, Alhusayen R, Lansang P, et al. What is hidradenitis suppurativa? Can Fam Physician. 2017;63:114-120.

6. Chiricozzi A, Raimondo A, Lembo S, et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity [abstract].Expert Rev Clin Immunol. 2016;12:1299-1308.

7. Owczarczyk-Saczonek A, Placek W. Compounds of psoriasis with obesity and overweight [abstract].Postepy Hig Med Dosw (Online). 2017;71:761-772.

This article originally appeared on Dermatology Advisor

Continue reading here:

Effects of Obesity on Skin - Endocrinology Advisor

TORONTO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Eli Lilly Canada announced today that Health Canada approved TALTZ (ixekizumab) on February 4, 2020, for the treatment of adult patients with active ankylosing spondylitis (AS), which is also known as radiographic axial spondyloarthritis (r-axSpA), who have responded inadequately to, or are intolerant to, conventional therapy. This is the third indication for TALTZ, which was first approved by Health Canada for moderate- to severe plaque psoriasis and psoriatic arthritis in 2016 and 2018, respectively.

People living with ankylosing spondylitis deal with a considerable amount of pain and anxiety. If left untreated, it can severely affect their mobility and mental wellbeing, says Dr. Doron Sagman, Vice President, R&D and Medical Affairs, Eli Lilly Canada. We are very pleased that TALTZ is now approved for the treatment of AS in Canada.

AS is a chronic inflammatory disease that often starts at the base of the spine in the sacroiliac joints around the pelvis, and can spread upwards to other parts of the spine; it is estimated to affect 300,000 Canadians.1

We are pleased to learn that a new medication to treat ankylosing spondylitis has been approved by Health Canada. Timely and equitable access to diverse treatment options are essential for patients living with this painful and debilitating condition, says Graeme Reed, interim President, Canadian Spondylitis Association.

The efficacy and safety of TALTZ in AS was demonstrated in two randomized, double-blind, placebo-controlled Phase 3 studies that included 657 adult patients with active AS: COAST-V in patients who are biologic disease-modifying antirheumatic drug (bDMARD)-nave, and COAST-W in patients who previously had an inadequate response or were intolerant to tumor necrosis factor (TNF) inhibitors.

In both studies2, the primary efficacy endpoint was the proportion of patients at 16 weeks achieving Assessment of Spondyloarthritis International Society 40 (ASAS40) response compared to placebo. ASAS40 measures disease signs and symptoms such as pain, inflammation and function. The COAST clinical trial program includes the first and only registration trials in AS to achieve ASAS40 response at 16 weeks as a primary endpoint.

Results from both studies demonstrated that patients treated with TALTZ achieved statistically significant and clinically meaningful improvements in signs and symptoms, as defined by ASAS40 response, compared to placebo. At 16 weeks, patients achieved ASAS40 at the following response rates:

Additionally, patients treated with TALTZ demonstrated statistically significant improvements in key secondary endpoints in both studies, including the proportion of patients at 16 weeks achieving ASAS20 at the following response rates:

TALTZ achieved a significant improvement over placebo in ASAS40 at Week 16, which is a more stringent endpoint than the commonly used ASAS20, says Dr. Proton Rahman, MD, FRCPC, Rheumatologist, St. Johns NL and COAST-W study investigator. Health Canadas approval is helpful for physicians who are looking for alternative treatment options and significant for our patients with AS.

Overall, the safety profile observed in patients with AS who were treated with TALTZ is consistent with the safety profile in patients with psoriasis.

About TALTZTALTZ (ixekizumab) is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. TALTZ inhibits the release of pro-inflammatory cytokines and chemokines.

About Lilly in RheumatologyLilly in rheumatology aims to create a brighter future for people with debilitating rheumatologic diseases through innovative discoveries and patient-centered solutions.

About Eli Lilly CanadaEli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet peoples needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism.

Story continues

Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto, which eventually produced the worlds first commercially-available insulin. Our work focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at http://www.lilly.ca.

For our perspective on issues in healthcare and innovation, follow us on twitter @LillyPadCA

Media Contact: Samira RehmanRehman_Samira@lilly.com 647-617-1994

REFERENCES1 Arthritis Society. https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/ankylosing-spondylitis2 TALTZ Product Monograph.

Original post:

Health Canada has approved TALTZ (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) - Yahoo...

The research report presents a detailed competitive analysis of the Psoriasis treatment Global Market 2019 market Share, Size, and Future scope 2026. This research report classifies the market by manufacturers, region, type, and applications.

The data presented in the graphical format gives a thorough understanding of the major players of Psoriasis treatment . The restraints and growth, industry plans, innovations, mergers, and acquisitions are covered in this report. The market is segmented based on key industry verticals like the product type, applications, and geographical regions.

Get a Sample Copy of the Report @ https://www.reportspedia.com/report/life-sciences/global-psoriasis-treatment-market-research-report-2020-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/54139 #request_sample

Key Players of Psoriasis treatment Report are:

Novartis International AGJohnson & JohnsonPfizer Inc.Merck and Co. Inc.AbbVie and AmgenEli Lilly

Short Description of Psoriasis treatment Market 2019-2026:

The Psoriasis treatment market was valued t XX Million US$ in 2019 and is projected to reach XX Million US$ by 2026, at a CAGR of XX% during 2019-2026. The research report gives historic report from 2013-2018.

The market is segmented into below points:

Market by Type/Products:

TNF InhibitorsPhosphodiesterase InhibitorsInterleukin BlockersOthers

Market by Application/End-Use:

OralTropicalInjectable

Enquire or share your questions if any before the purchasing this report @ https://www.reportspedia.com/report/life-sciences/global-psoriasis-treatment-market-research-report-2020-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/54139 #inquiry_before_buying

Outline of the data covered in this study:

The market study covers the forecast Psoriasis treatment information from 2019-2026 and key questions answered by this report include:

In this study, the years considered to estimate the market size of Psoriasis treatment are as follows:

Historic Period: 2015-2019.

Base Year: 2019.

Estimated Year: 2020.

Forecast Year 2020 to 2026.

Significant Features that are under Offering and Key Highlights of the Reports:

Table of contents:

For More TOC Content Continued,

Get A Sample Pdf Copy Of Table Of Content Describing Current Value And Volume Of The Market With All Other Essential Information @ https://www.reportspedia.com/report/life-sciences/global-psoriasis-treatment-market-research-report-2020-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/54139 #table_of_contents

Thanks A Million For Reading! You Can Also Request Custom Information Like Chapter-Wise Or Specific Region-Wise Study As Per The Given Specifications.

Link:

Global Psoriasis treatment Market Is Estimated To Expand At a Healthy CAGR in Upcoming year 2020-2026 - News Times

Red, scaly patches on your skin can be embarrassing, and you might do your best to hide them when youre out in public.

If you are living with these signs of psoriasis, however, you are far from alone. In the United States, about 8 million people have a form of psoriasis.

Psoriasis can cause significant discomfort, both physically and emotionally. It is more than just dry skin, and treating it is important to improve quality of life.

Read on to learn more about this condition, who is at risk, the complications and how it is treated and prevented.

Psoriasis is a hereditary skin condition that causes areas of the skin to shed rapidly. It can cause patches of raised skin or blisters on the scalp, elbows, knees, trunk or lower back. It is a chronic condition that can return multiple times. There are many kinds of psoriasis, with plaque psoriasis being the most common form.

People with a family history of psoriasis have a higher risk of developing it themselves. It can be triggered by stress or emotional disorders, or even by certain types of medication. Infections or skin injuries can also cause a flare-up.

A common side effect of psoriasis is psoriatic arthritis, which affects between 10 and 30 percent of people with the condition. Psoriatic arthritis causes inflammation in the joints and may damage joints permanently. People with psoriasis also have a higher chance of developing diabetes, heart disease and other serious conditions.

Various treatments can improve psoriasis symptoms. Topical treatments include steroid creams, vitamin A or vitamin D3 creams, and moisturizers. Medications are also available, though some are reserved for severe cases due to serious potential side effects. Ultraviolet light treatments can also reduce inflammation.

Treatment for your psoriasis can vary as you age because your body may react differently to medications and your skin can change over time, says Dan Bushnell, administrator at Gramercy Court Assisted Living. If you begin to experience new side effects, or if treatments dont work as well as they did in the past, be sure to talk to your doctor about other options.

Psoriasis is hereditary, and there is no way to prevent a person from developing the condition at some point. However, avoiding triggers like stress, sunburns and infections can keep flare-ups at bay. Caring for your skin can keep the condition under control. Use creams, lotions and humidifiers to keep your skin moist. Watch out for medications that increase your risk for a flare-up.

Psoriasis can have a major impact on your quality of life, especially if you are dealing with a severe case. While this condition cant be cured, there are treatments to improve symptoms and reduce flare-ups. If you are experiencing psoriasis symptoms, work with your physician to find the right treatment to keep it from running your life.

Dr. Amy Osmond Cook is a health care technology consultant and VP of marketing at Simplus, a platinum Salesforce partner.

More here:

Five things you should know about psoriasis - Daily Herald

Skyrizi, a key drug in AbbVies post-Humira future, has added another feather to its cap.

On Tuesday, the IL-23 inhibitor emerged superior in a head-to-head327-patient trial against Novartis dominant Cosentyx in patients with moderate-to-severe plaque psoriasis.

Data showed Skyrizi induced significantly higher rates of skin clearance compared to Cosentyx, meeting the primary goal of superiority with at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) at week 52. Overall, 87% of Skyrizi-treated patients hit PASI 90, versus 57% of Cosentyx-treated patients at the one year mark.

The other main goal of non-inferiority at week 16 74% of Skyrizi patients achieved PASI 90 compared to 66% of Cosentyx patients was also met. Skyrizi also eclipsed Cosentyx on all secondary endpoints, including PASI 100, and PASI 75.

In the fall of 2017, Skyrizi was evaluated against J&Js Stelara and its own Humira in a psoriasis study and emerged victorious, handsomely outpacing the rival drugs in clearing psoriasis.

These head-to-head studies are key to establishing Skyrizis position in a crowded market, which includes Humira, Novartis anti-IL17 Cosentyx, J&Js anti-IL23 Tremfya, anti-IL12/23 Stelara, as well as Lillys anti-IL17 Taltz.

Skyrizi is not the first pure IL-23 inhibitor to be approved Tremfya was approved in 2017 and Ilumya in 2018. But the AbbVie drug has a dosing advantage over Tremfya it is administered every 12 weeks, versus once every two months for Tremfya, SVB Leerinks Geoffrey Porges said on Wednesday, noting that other psoriasis biologics in addition to the oral Otezla generated a combined $11.1 billion in 2018 sales.

This does not include sales of anti-TNFs in psoriasis, which should decrease as patients move to these new, more efficacious therapies. These products also all achieved $500 million $1 billion in the second year of launch, which is likely to also be achieved by Skyrizi, SVB Leerinks Geoffrey Porges wrote in a note last year.

Overall biologics are still used in only 30% of the moderate to severe psoriasis population, (per JNJ in 2017), and AbbVies Skyrizi should benefit from both best-in-category efficacy (i.e. market share gains) and the continued rapid market expansion.

Skyrizi was approved in April 2019. AbbVie paid Boehringer Ingelheim $595 million upfront to license rights to the drug, known chemically as risankizumab, in early 2016.Evaluate has pegged Skyrizi as the number 3 blockbuster on its list of heavyweight drugs launched in 2019, estimating the drug could earn more than $2 billion in 2024 a far cry from AbbVies homegrown estimate of $4 billion to $5 billion in peak sales. Porges has forecast adjusted peak annual sales of $3 billion.

Last August, Lillys Taltz beat J&Js Tremfya in a head-to-head psoriasis study. In 2018, J&J ran its own head-to-head psoriasis trial against Cosentyx and came out with data that showed Tremfya superseded Novartis dominant rival.

Social image: AbbVie

Continue reading here:

AbbVie's Skyrizi hangs Novartis' Cosentyx out to dry in head-to-head psoriasis study - Endpoints News

A new study evaluated healthcare utilization among psoriatic arthritis (PsA) patients in the years leading up to their diagnosis. The researchers concluded here that PsA patients are significantly more likely to have medical visits than other patients during the time period leading up to their diagnosis, going back as far as five years.

PsA is a heterogeneous disease that can present in various clinical manifestations, such as synovitis, enthesitis, dactylitis and spondylitis, the study authors explained. Some of these features can present with only minimal findings on physical examination, and the differentiation from other conditions, such as osteoarthritis, can be challenging. Furthermore, unlike RA and lupus, PsA has no reliable diagnostic biomarkers. These factors, along with the lack of awareness of PsA among patients and primary care physicians, and limited access to specialty care contribute to delays in the diagnosis of PsA.

Better pre-diagnosis may be beneficial to disease treatment and outcomes, the researchers noted, so they explored the burden of musculoskeletal symptoms among patients who were eventually diagnosed with PsA.

The study was a population-based, matched cohort study that collected data from electronic medical records and administrative data in Ontario, Canada. PsA patients were age- and sex-matched to control patients from the same family physicians. Control patients were eligible for inclusion if they did not have a billing code indicating a diagnosis of spondyloarthritis, ankylosing spondylitis, or rheumatoid arthritis. Outcomes included healthcare utilization and costs pertaining to nonspecific musculoskeletal issues over the five-year period leading up to the index date.

Final analysis included 462 PsA patients and 2,310 controls (mean [SD] age, 54.2 [13.8] years; 55.6% were female). PsA patients were significantly more likely to visit a primary care physician for nonspecific musculoskeletal issues in the year leading up to the index date (odds ratio [OR]=2.14; 95% confidence interval [CI], 1.732.64); this trend was also observed in the five years leading up to the index date (OR=1.76; 95% CI, 1.432.18). PsA patients were also more likely than the controls to require musculoskeletal-related specialty care, diagnostic imaging and procedures prior to the index date. PsA patients were more likely to be assessed by nonrheumatologist musculoskeletal specialists (OR range, 1.592.03), visit an emergency department for musculoskeletal-related issues (OR range, 1.332.69), and have joint imaging (OR range, 3.206.26) and joint injections (OR range, 4.639.26).

Over the five years before index date, PsA patients were at least four times more likely than the controls to visit a rheumatologist. The most common diagnosis codes rheumatologists provided were for other disease of the musculoskeletal systems, psoriasis, osteoarthritis, and cramps, leg pain, muscle pain, joint pain, joint swelling.

The study appeared in Arthritis Care & Research.

The study authors concluded of the findings, his pattern reveals some of the underlying causes of diagnosis delays of PsA and highlights the need for diagnostic strategies and novel reliable biomarkers to aid in early diagnosis of PsA.

Continue reading here:

PsA Patients Have More Medical Visits in Five Years Leading Up to Diagnosis - DocWire News

BACKGROUND:

Real-world studies evaluating patients with challenging-to-treat localizations of psoriasis (scalp, nail, and palmoplantar) are limited.

To characterize patients with versus without psoriasis in challenging-to-treat areas seen in routine US clinical practice.

This retrospective observational study included all adult patients with psoriasis enrolled in the Corrona Psoriasis Registry between April 2015 and May 2018 who initiated a biologic therapy at registry enrollment. Patients were stratified by the presence of scalp, nail, or palmoplantar psoriasis (nonmutually exclusive groups). Patient demographics, clinical char-acteristics, disease activity, and patient-reported outcome measures (pain, fatigue, itch, EuroQol visual analog scale [EQ VAS], Dermatology Life Quality Index [DLQI], and Work Productivity and Activity Impairment questionnaire [WPAI]) were assessed at registry enrollment and compared between patients with versus without each challenging-to-treat area using nonparametric Kruskal-Wallis tests for continuous variables and 2 or Fisher exact tests for categorical variables. Generalized linear regression models were used to estimate differences in disease activity and patient-reported outcomes between patients with versus without each challenging-to-treat area.

Among 2,042 patients with psoriasis (mean age [SD], 49.6 14.7 years; 51.5% male), 38.4% had psoriatic arthritis (PsA), 38.1% had scalp psoriasis, 16.0% had nail psoriasis, 10.9% had palmoplantar psoriasis, and 26.2% had a combination of 2 challenging-to-treat areas and PsA; only 34.2% had body plaque psoriasis without PsA or challenging-to-treat areas. Patients in all challenging-to-treat groups reported higher (mean [95% CI]) itch (scalp, 58.01 [57.62-58.40] vs. 54.35 [53.99-54.72]; nail, 56.42 [56.02-56.81] vs. 55.59 [55.20-55.97]; palmoplantar, 60.22 [59.86-60.59] vs. 55.15 [54.79-55.54]) and lower EQ VAS (scalp, 68.12 [67.78-68.48] vs. 69.46 [69.12-69.81]; nail, 66.21 [65.89-66.55] vs. 69.48 [69.14-69.83]; palmoplantar, 66.21 [66.07-66.75] vs. 69.29 [68.94-69.94]) scores than those without the respective challenging-to-treat localization. Patients with nail or palmoplantar psoriasis reported higher pain, fatigue, and DLQI scores than those without. Higher proportions of patients with scalp or palmoplantar psoriasis reported work impairment compared with those without.

Two-thirds of patients with psoriasis who initiated biologic therapy had PsA and/or 1 challenging-to-treat area. Patients with challenging-to-treat areas had worse patient-reported outcome scores than those without, indicating a significant burden of challenging-to-treat areas on patients quality of life.

See more here:

Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry - DocWire News

Psoriasis is a skin infection that's caused due to multiple reasons. Read below to find out how you can treat psoriasis at home with these doable home remedies.

When it comes to taking care of our skin, we all make sure to apply creams and soaps that maintain the moisture and pH levels of our skin. However, some skin ailments are caused in spite of taking care of our skin. Lifestyle choices, stress and various other factors contribute to these ailments. And one such ailment is psoriasis.

Psoriasis is a skin condition which appears on various parts of the body like knees, elbows, scalp, and the torso. This ailment can be identified when you have thick, red skin with silver-white patches on your body, which are also known as scales. If not taken care of, these patches and scales can get itchy and painful with time. If you are suffering from this ailment, then here are some home remedies for it. However, if the condition worsens it's better to consult a dermatologist.

Here are some home remedies for psoriasis:

When it comes to treating this skin infection at home, plastic wraps can prove to be quite effective. If you are suffering from this skin condition, then you should wrap the affected area with plastic covers, mostly after applying their prescribed medication or ointment. It is done to help the body hold onto the vital natural oils and water.

Sea salt and Epsom salt again helps to deal with psoriasis. Sea salt will ensure removal of thick scales caused due to psoriasis, thus ensuring deeper penetration of the medication into the skin. They are known for their exfoliating properties and hence can provide relief from psoriasis.

Using apple cider vinegar in the affected areas can reduce the itching, pain and burning sensation to a great extent. It is a popular disinfectant and is popular for its properties and considerably benefits people suffering from this condition.

Drinking bitter gourd juice with lime on an empty stomach can again provide some relief from psoriasis. However, one needs to do this daily, since it takes about 5-6 months to show effective results.

You can also treat psoriasis by adding some additional dietary supplements to your routine diet. Vitamin D, aloe vera, fish oil are a few supplements which may help ease psoriasis symptoms.

Reduce fatty snacks and red meat. Add nuts, seeds and foods rich in Omega-3 fatty acids. With an ability to reduce inflammation, theyre the perfect foods for your psoriasis.

Read the original here:

Remedies for Psoriasis: THESE home treatments can help you deal with this skin infection - PINKVILLA

Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.

These patches normally appear on your elbows, knees, scalp and lower back, but can appear anywhere on your body.

Most people are only affected with small patches. In some cases, the patches can be itchy or sore.

Psoriasis affects around 2% of people in the UK. It can start at any age, but most often develops in adults under 35 years old, and affects men and women equally.

The severity of psoriasis varies greatly from person to person. For some it's just a minor irritation, but for others it can majorly affect their quality of life.

Psoriasis is a long-lasting (chronic) disease that usually involves periods when you have no symptoms ormild symptoms, followed by periods when symptoms are more severe.

People with psoriasis have anincreased production of skin cells.

Skin cells are normallymade and replaced every 3 to 4 weeks, but in psoriasis this process only takes about 3 to 7 days.

The resulting build-up of skin cells is what creates the patches associated with psoriasis.

Although the process is not fully understood, it's thoughtto be related to a problem with the immune system.

The immune systemis your body's defence against disease and infection, but it attacks healthy skin cells by mistake in people with psoriasis.

Psoriasis can run in families,although the exact role genetics plays in causing psoriasis is unclear.

Many people's psoriasis symptoms start or become worse because of a certain event, known as a trigger.

Possible triggers of psoriasis includean injury to your skin, throat infections and using certain medicines.

The condition is not contagious, so it cannot be spread from person to person.

Find out more about the causes of psoriasis

A GP canoften diagnose psoriasis based on the appearance of your skin.

In rare cases, a small sample of skin called a biopsy will be sent to the laboratory for examination under a microscope.

This determines the exact type of psoriasis and rules out other skin disorders, such as seborrhoeic dermatitis, lichen planus, lichen simplex and pityriasis rosea.

You may be referred to a specialist in diagnosing and treating skin conditions (dermatologist) if your doctor is uncertain about your diagnosis, or if your condition is severe.

If your doctor suspects you have psoriatic arthritis, which is sometimes a complication of psoriasis, you may be referred to a doctor who specialises in arthritis (rheumatologist).

You may have blood tests to rule out other conditions, such as rheumatoid arthritis, and X-rays of the affected joints may be taken.

There's no cure for psoriasis, but a range of treatments can improve symptoms and the appearance of skin patches.

In most cases, the first treatment used will be a topical treatment, such as vitamin D analogues or topical corticosteroids. Topical treatments are creams and ointments applied to the skin.

If these are not effective, or your condition is more severe, a treatment called phototherapy may be used. Phototherapy involves exposing your skin to certain types of ultraviolet light.

In severe cases, where the above treatments are ineffective, systemic treatments may be used. These are oral or injected medicines that work throughout the whole body.

Although psoriasis is just a minor irritation for some people, it can have a significant impact on quality of life for those more severely affected.

For example,some people with psoriasis have low self-esteem because of the effect the condition has on their appearance.

It's also quitecommonto developtenderness, pain and swelling in the joints and connective tissue. This is known as psoriatic arthritis.

Speak to a GP or your healthcare team if you have psoriasis and youhave any concerns about your physical and mental wellbeing. Theycan offer advice and further treatment if necessary.

There are also support groups for people with psoriasis, such as The Psoriasis Association, where you can speak to other people with the condition.

Find out more about living with psoriasis

Media last reviewed: 5 November 2018Media review due: 5 November 2021

Page last reviewed: 9 May 2018Next review due: 9 May 2021

Continued here:

Psoriasis - NHS